Novavax, Inc. is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on drug delivery and biological technologies.
The Company’s research is focused on developing its technology platforms in drug delivery: micellar nanoparticle (MNP), Novasomes® and Sterisomes®, to enhance the delivery of FDA approved drugs to provide patients with better clinical outcomes. ESTRASORB®, a topical emulsion for estrogen therapy, is its first internally developed FDA-approved topical formulation which uses MNP technology. Novavax also focuses on developing its Virus Like Particle (VLP) technology into vaccines for the prevention of infectious diseases such as HIV/AIDS, pandemic flu, seasonal flu and SARS. Additionally, the biologicals division is developing E-selectin tolerogen in conjunction with the National Institute of Neurological Disorders and Stroke for the prevention of illness where inflammatory and immune responses are involved.
Novavax has a strong commitment to business ethics, and believes that every employee must conduct themselves with honesty, integrity and respect, and in compliance with all applicable laws. To maintain their employment with the company, each employee must be in compliance with the Novavax Code of Business Conduct and Ethics.
Headquartered in Malvern, Pennsylvania, Novavax also maintains additional research facilities in Rockville, Maryland, as well as a 24,000 square foot, state of the art commercial manufacturing facility within Cardinal Health’s Philadelphia, Pennsylvania complex.
Novavax Reports Positive Data from RSV F-Protein Recombinant Nanoparticle Vaccine Phase 1 Clinical Trial
Novavax RSV F-Protein Recombinant Nanoparticle Vaccine Candidate Highly Immunogenic in Preclinical Maternal Immunization Model
Full Data Set from Novavax RSV F Vaccine Clinical Trial Published in Journal of Infectious Disease
Novavax Reports Top-Line Data from Phase 2 Clinical Trial of Recombinant Quadrivalent Seasonal Influenza VLP Vaccine Candidate
WHO Teleconference: Novavax Reports Top-Line Data from Ebola GP Recombinant Nanoparticle Vaccine Clinical Trial
Novavax Provides Latest Data from NHP Ebola Challenge at International Symposium on Filoviruses
Novavax Commences Enrollment in Phase 1 Clinical Trial of Ebola GP Vaccine
Novavax' Nanoparticle Vaccine for Infant Protection via Maternal Immunization Granted FDA Fast Track Designation
Enrollment Begins for Phase 2 Clinical Trial of Novavax’ Seasonal Influenza VLP
Enrollment Begins in Phase 1 Clinical Trial of Novavax’ RSV F-Protein Nanoparticle Vaccine
Novavax' H7N9 VLP Vaccine Candidate Adjuvanted with Matrix-M Granted FDA Fast Track Designation
Novavax Presents Ebola GP Recombinant Nanoparticle Vaccine Candidate at 8th Vaccine and ISV Conference
New Data from Novavax' RSV F-Protein Nanoparticle Vaccine Trial Presented at 8th Vaccine & ISV Congress
Novavax’s RSV F-Protein Nanoparticle Vaccine Candidate Evokes Polyclonal Antibody Response to Antigenic Site II
Novavax Begins Enrollment in Phase 2 Clinical Trial of RSV F Nanoparticle Vaccine
Novavax Reports Positive Data from Phase 1/2 Clinical Trial of H7N9 VLP with Matrix-M
Novavax Begins Phase 2 Clinical Trial of RSV F-Protein Nanoparticle Vaccine
Pre-Clinical Data on Pregnant Baboons Immunized with Novavax RSV F Nanoparticle Vaccine Presented at 54th ICAAC
Novavax to Present Data from Preclinical Studies of RSV F Nanoparticle Vaccine at ICAAC 2014
Novavax Reports One Year Follow-Up Data from RSV F-Protein Vaccine Candidate Phase 1 Elderly Trial
Experimental Protein Nanoparticle Vaccine Shows Potential to Respond Rapidly to Emerging Viruses
Novavax Unveiled Evaluation Data of RSV-F Protein Nanoparticle Vaccine in Clinical Trial
Novavax Initiates Phase 1/2 Clinical Trial of its H7N9 Avian Influenza VLP Vaccine Candidate
Novavax and HHS-BARDA Extend Contract for Development of Recombinant Influenza Vaccines
Novavax Continues Partnership with PATH to Develop RSV Vaccine for Maternal Immunization
Positive Clinical Trial Data of Novavax' H7N9 VLP Vaccine Published in New England Journal of Medicine
Novavax Begins Enrollment in RSV Vaccine Phase 2 Dose-Confirmatory Clinical Trial
Nanoparticle Vaccine Developer, Novavax to Start Pandemic and Seasonal Influenza Trials in 2014
Novavax Reports Positive Findings from RSV F Nanoparticle Vaccine Studies at 53rd ICAAC
Positive Results from Novavax Phase 1 Trial of Nanoparticle RSV Vaccine
Positive Data from Novavax Phase II RSV F Protein Nanoparticle Vaccine Clinical Trial
Novavax Presents RSV Nanoparticle Vaccine Preclinical Findings at ISRVI 2013
Novavax Begins Phase 1 Clinical Trial of Nanoparticle-Based RSV Vaccine Candidate
Novavax Presents Preclinical and Clinical Findings for its RSV Vaccine
Novavax to Discuss Phase I Study Results of RSV Nanoparticle Vaccine at Turkey Conference
Dr. Yitong Dong
Dr. Yitong Dong has recently been awarded funding to study custom composite nanocrystals, which could help to create advanced quantum communication technologies. Learn more about this project in this interview.
Roey Elnathan, Ph.D.
We take a closer look at the fusion of nanotechnology and CAR-T therapy through our interview with Dr. Roey Elnathan about a new approach that harnesses the capabilities of nanoneedles to efficiently deliver genetic materials to target cells.
In this interview, Laura-Isabelle, the Director of Sales at Photon etc., talks to AzoNano about how spectral imaging can help improve the next generation of solar cells.
The Verifire™ interferometer system provides fast and reliable measurements of surface form error.
Discover the compact, fast rotary table V-610 for precision testing and manufacture.
The Diamond Interaction Chamber (DIXC) is integral to the NanoGenizer high-pressure homogenizer.